Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 4.4% in the afternoon session after investment firm Stifel reiterated its Buy rating and maintained a $207.00 price ...

Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...

Repligen (RGEN) released its third quarter results, revealing year-over-year growth in both revenue and net income. The company shifted from last year’s net loss into positive territory and also ...

Repligen (NASDAQ:RGEN) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns, ...

In the latest quarter, 4 analysts provided ratings for Repligen (NASDAQ:RGEN), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

Repligen's CDMO business marked its highest revenue in 18 months, with a significant growth across various franchises, including a mid-single-digit revenue increase in pharma and a 20% growth in CDMO ...

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...